INMD vs. SLNO, BLFS, CNMD, AXGN, OM, CUTR, LIVN, ITGR, TMDX, and MASI
Should you be buying InMode stock or one of its competitors? The main competitors of InMode include Soleno Therapeutics (SLNO), BioLife Solutions (BLFS), CONMED (CNMD), AxoGen (AXGN), Outset Medical (OM), Cutera (CUTR), LivaNova (LIVN), Integer (ITGR), TransMedics Group (TMDX), and Masimo (MASI). These companies are all part of the "electromedical equipment" industry.
InMode (NASDAQ:INMD) and Soleno Therapeutics (NASDAQ:SLNO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership, community ranking and valuation.
In the previous week, Soleno Therapeutics had 2 more articles in the media than InMode. MarketBeat recorded 9 mentions for Soleno Therapeutics and 7 mentions for InMode. InMode's average media sentiment score of 0.99 beat Soleno Therapeutics' score of 0.19 indicating that InMode is being referred to more favorably in the media.
InMode currently has a consensus price target of $32.80, indicating a potential upside of 77.68%. Soleno Therapeutics has a consensus price target of $60.33, indicating a potential upside of 30.70%. Given InMode's higher possible upside, research analysts plainly believe InMode is more favorable than Soleno Therapeutics.
Soleno Therapeutics received 143 more outperform votes than InMode when rated by MarketBeat users. However, 75.12% of users gave InMode an outperform vote while only 71.43% of users gave Soleno Therapeutics an outperform vote.
InMode has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.
InMode has a net margin of 38.84% compared to Soleno Therapeutics' net margin of 0.00%. InMode's return on equity of 26.15% beat Soleno Therapeutics' return on equity.
InMode has a beta of 2.2, suggesting that its stock price is 120% more volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of -1.51, suggesting that its stock price is 251% less volatile than the S&P 500.
68.0% of InMode shares are owned by institutional investors. Comparatively, 97.4% of Soleno Therapeutics shares are owned by institutional investors. 6.9% of InMode shares are owned by insiders. Comparatively, 12.3% of Soleno Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
InMode beats Soleno Therapeutics on 11 of the 18 factors compared between the two stocks.
Get InMode News Delivered to You Automatically
Sign up to receive the latest news and ratings for INMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
